Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IPGP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIPG Photonics to acquire Lumibird Medical for €300M to expand into ophthalmology lasers
Filed July 17, 2026 · Period ending July 16, 2026 · ~1 min read
Key Changes
-
high
IPG entered a binding agreement to acquire Lumibird Medical for €300M cash (~$349M) plus up to €50M earnout tied to 2026-2027 performance, funded from existing cash; closing expected Q4 2026 pending French labor consultation and regulatory approvals.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Acquisition adds ~$1B addressable market in ophthalmology, combining with IPG's existing $74M medical business (urology/dermatology) to create a scaled medical laser platform representing ~26% of pro forma revenue, up from 16%.
Exhibit 99.2 view on EDGAR → -
high
Lumibird Medical generated €112.2M revenue with 21.5% EBITDA margin in FY2025; IPG expects the acquisition to be accretive to gross margin, EBITDA, and adjusted EPS by adding a high-margin business.
Exhibit 99.1 view on EDGAR → -
medium
Purchase price of €300M represents 15.9x Lumibird Medical's adjusted EBITDA for FY2025; target holds #1 market positions in anterior chamber lasers, retina lasers, and ultrasound imaging for ophthalmology with 80,000+ installed systems globally.
Exhibit 99.2 view on EDGAR → -
medium
If seller completes French labor consultation but does not exercise the put option by the deadline, seller must pay IPG €3.5M as IPG's sole remedy; IPG secured warranty and indemnity insurance with seller's direct liability for business warranties capped at €1 except for fraud.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
The purchase price of 15.9x adjusted EBITDA reflects Lumibird Medical's market leadership positions and premium positioning in non-discretionary medical spending categories including cataracts, glaucoma, dry eye, and retinal conditions. The target operates three facilities with 450+ employees and maintains over 80,000 installed systems globally. IPG is funding the transaction from existing cash and expects to preserve financial flexibility post-closing.
The transaction structure uses a put option that becomes exercisable after completion of a French labor consultation process, with closing expected in Q4 2026 subject to French foreign investment approval and customary conditions. IPG has secured warranty and indemnity insurance to cover potential breaches of seller representations, limiting the seller's direct liability to €1 for business warranties except in cases of fraud.
Section-by-Section Diff
Event · Exhibit 99.2
Added in current filing · view on EDGAR →
Purchase price of €300 million represents 15.9x adjusted EBITDA for FY2025 ... • Contingent earnout up to €50 million based on financial performance in FY2026 and 2027
IPG Photonics is acquiring Lumibird Medical, a global leader in medical lasers for ophthalmology, for €300 million (approximately $348.8 million at the disclosed exchange rate of US$1=euro 0.86). The purchase price represents 15.9x Lumibird Medical's adjusted EBITDA for fiscal year 2025. An additional contingent earnout of up to €50 million may be paid based on Lumibird Medical's financial performance in 2026 and 2027. The transaction is funded through cash on hand and is expected to close in Q4 2026, subject to consultation with Lumibird Medical's works council, regulatory approvals, and customary closing conditions.
Added in current filing · view on EDGAR →
Creates a scaled medical laser platform Establishes leadership in Ophthalmology laser treatment and diagnostic systems, complementing IPG’s growth in Urology and increasing addressable market by approximately $1 billion
The acquisition expands IPG's medical laser portfolio into ophthalmology, adding approximately $1 billion in addressable market opportunity. Lumibird Medical generated €112.2 million in net sales for fiscal year 2025 with a 16.8% adjusted EBITDA margin. Combined with IPG's existing $74 million medical business (primarily urology and dermatology), the pro forma medical segment will represent approximately 26% of IPG's total revenue, up from 16% previously. Lumibird Medical has over 80,000 global installed systems and operates three facilities with 450+ employees.
Added in current filing · view on EDGAR →
Adds a high-margin business that is expected to be accretive to margins, EBITDA, and adjusted EPS
IPG states the acquisition will be accretive to gross margin, EBITDA, and adjusted earnings per share. Lumibird Medical's 16.8% adjusted EBITDA margin and premium positioning in medical markets are expected to enhance IPG's overall profitability. The company maintains it will preserve a strong balance sheet and financial flexibility after funding the transaction with cash on hand.
Added in current filing · view on EDGAR → · paraphrased
Designs and produces medical diagnostic and treatment solutions for ophthalmology • Established leader with strong brand recognition, broad product portfolio, and >80,000 global installed systems • Robust R&D organization and capabilities with >50 employees • Significant IP portfolio with patents and proprietary technology
Lumibird Medical is a global leader in ophthalmology lasers and diagnostics, holding the #1 market position in anterior chamber lasers, retina lasers, and ultrasound imaging for ophthalmology. Its product portfolio includes treatments for dry eye, glaucoma, cataracts, and retinal conditions, as well as diagnostic imaging systems. The company has over 50 R&D employees and a significant intellectual property portfolio. Geographically, sales are distributed across Europe (32%), Asia (28%), North America (27%), and rest of world (13%), with China representing approximately 5% of sales.
Added in current filing · view on EDGAR →
Consultation process with Lumibird Medical’s works council • Subject to regulatory approvals and customary closing conditions • Expected to close in Q4 2026
The transaction is subject to completion of the information and consultation process with Lumibird Medical's works council, receipt of required regulatory approvals, and satisfaction of customary closing conditions. IPG expects the acquisition to close in the fourth quarter of 2026. The company held a conference call on July 17, 2026 at 8:00 am ET to discuss the transaction.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
The acquisition advances IPG’s strategy, further expanding the Advanced Solutions portfolio in attractive medical markets. ... IPG believes that the combined medical businesses will create a scaled medical laser platform for growth with complementary established leadership in ophthalmology and urology. The company expects that this also adds approximately $1 billion in addressable market for Advanced Solutions, expanding long-term value creation opportunities that leverage IPG’s capabilities.
The acquisition expands IPG's Advanced Solutions portfolio in medical markets by combining Lumibird Medical's ophthalmology leadership with IPG's urology strength. IPG expects this creates a scaled medical laser platform and adds approximately $1 billion in addressable market for Advanced Solutions, expanding long-term value creation opportunities.
Added in current filing · verify on EDGAR →
Following completion of the information and consultation process with Lumibird Medical's works council in accordance with French law, the parties expect to enter into a definitive purchase agreement. IPG Photonics expects the transaction to close during the fourth quarter of 2026, subject to customary closing conditions.
The parties expect to enter into a definitive purchase agreement following completion of the French works council consultation process. IPG expects the transaction to close in Q4 2026, subject to customary closing conditions.
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Under the Put Option Agreement, following completion of the information and consultation process with the works council of the Economic and Social Unit (Unité économique et sociale) of the Seller required under Article L. 2312-8 of the French Labor Code (the "Consultation Process") and delivery by the Seller of a notice of exercise, the Company is irrevocably committed to execute and deliver the SPA (together with its respective annexes, schedules or appendixes) concurrently with the execution and delivery by the Seller on the date and location set forth in the put option exercise notice. The Put Option is irrevocable and remains in force until the earliest of (i) the tenth (10th) business day after completion of the Consultation Process, (ii) six months after the date of the Put Option Agreement, and (iii) the date of execution of the SPA (the "Expiry Date"). In consideration for the Company’s undertakings under the Put Option Agreement, the Seller granted the Company an exclusivity undertaking that remains in effect until the earlier of (i) the date that is nine (9) months from the date of the Put Option Agreement and (ii) the execution of the SPA following exercise of the put option.
The put option gives the seller the right to force IPG to complete the acquisition after completing a French labor consultation process. The option expires after the earlier of 10 business days post-consultation, six months from signing, or execution of the definitive purchase agreement. In exchange for IPG's binding commitment, the seller granted IPG exclusivity for up to nine months, preventing the seller from negotiating with other potential buyers during that period.
Added in current filing · verify on EDGAR →
The Put Option Agreement also provides that, if the Consultation Process has been completed (or deemed completed) and the Seller does not deliver an exercise notice on or before the Expiry Date, the Seller will be required to pay the Company €3.5M, which is the Company's exclusive remedy in such circumstance.
If the seller completes the required labor consultation but chooses not to exercise the put option by the deadline, the seller must pay IPG €3.5 million as IPG's sole remedy. This compensates IPG for its exclusivity commitment and transaction preparation costs if the seller walks away after the consultation is complete.
Added in current filing · verify on EDGAR →
If the Put Option is exercised by the Seller, under the SPA, the Seller would make certain fundamental representations and warranties regarding Lumibird Medical and agrees to indemnify the Company to the extent the Company’s losses related to such fundamental representations and warranties exceed the coverage available under the W&I Policy referenced below. The Seller will also give business warranties for the sole purpose of the W&I Policy referenced below, with Seller’s aggregate liability capped at one euro (€1.00), except in the case of fraud or willful misconduct. In addition, as part of the Acquisition, the Company has secured a warranty and indemnity insurance policy (the “W&I Policy”) insuring for losses arising out of certain breaches of the representations and warranties of the Seller in the SPA, subject to a retention amount, exclusions, policy limits and certain other terms and conditions.
IPG has secured warranty and indemnity insurance to cover potential breaches of the seller's representations and warranties about Lumibird Medical. The seller's direct liability for business warranties is capped at €1, with the insurance policy providing the primary protection. The seller retains indemnification obligations for fundamental representations beyond what the insurance covers, and full liability in cases of fraud or willful misconduct.
Added in current filing · verify on EDGAR →
The parties’ obligations to complete the transaction under the SPA will be subject to certain customary conditions and approvals, including authorization by the French Minister of the Economy under the French foreign direct investment regime. The closing is expected to occur in the fourth quarter of 2026.
The acquisition requires approval from the French Minister of the Economy under France's foreign direct investment review process, along with other customary closing conditions. IPG expects to close the transaction in the fourth quarter of 2026, approximately $1 billion three to six months from the announcement date.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 21, 2026 · How we verify